Results 201 to 210 of about 53,615 (314)

The role of 5‐alpha reductase inhibitors in transurethral resection of the prostate: a meta‐analysis of randomised controlled trials

open access: yesBJU International, Volume 137, Issue 3, Page 430-443, March 2026.
Objective To critically evaluate the existing evidence base surrounding the efficacy of preoperative 5‐alpha reductase inhibitor (5ARI) administration in the reduction of perioperative complication rates in transurethral resection of prostate (TURP). Methods In April 2025, a systematic search of on‐line databases was conducted to identify randomised ...
Cian M. Hehir   +5 more
wiley   +1 more source

Relationship between patient activation, experienced stigma, and internalised weight stigma in people with type 2 diabetes

open access: yesDiabetic Medicine, Volume 43, Issue 3, March 2026.
Abstract Aims Patient activation is associated with disease self‐management; limited research has examined the role of perceived stigmatisation in this relationship. We explored links between diabetes and weight stigma, internalised weight stigma, and patient activation among people with type 2 diabetes (T2D).
Tracy J. Sims   +3 more
wiley   +1 more source

Efficacy and safety of CT‐868, a novel, fully biased, dual glucagon‐like peptide‐1/glucose‐dependent insulinotropic polypeptide receptor agonist, in type 2 diabetes: A double‐blind, randomized placebo controlled phase 2 trial

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 3, Page 1673-1682, March 2026.
Abstract Aims To assess the glycaemic efficacy and safety of CT‐868, a cAMP signal‐biased, dual glucagon‐like peptide‐1/glucose‐dependent insulinotropic polypeptide receptor agonist, in participants with type 2 diabetes (T2D). Materials and Methods This 26‐week (W), phase 2, randomized, double‐blind placebo‐controlled trial enrolled adults with T2D ...
Manu V. Chakravarthy   +10 more
wiley   +1 more source

Associations between microaggressions, depression, anxiety, and alcohol use among Black young adults: findings from a pilot study. [PDF]

open access: yesFront Public Health
Cavazos-Rehg PA   +10 more
europepmc   +1 more source

Efficacy and safety of combining empagliflozin in people with type 2 diabetes mellitus uncontrolled with metformin and sitagliptin: A randomised, double‐blind, multicentre, therapeutic confirmatory phase 3 clinical trial

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 3, Page 2027-2037, March 2026.
Abstract Aim This study evaluated the efficacy and safety of empagliflozin 10 and 25 mg compared to placebo as add‐on treatment for people with type 2 diabetes mellitus (T2DM) uncontrolled after ≥8 weeks of treatment with metformin and sitagliptin. Materials and Methods A randomised, double‐blind, multicentre, therapeutic confirmatory, phase 3 clinical
Seung‐Hwan Lee   +15 more
wiley   +1 more source

Early response rates with adjunctive cenobamate in uncontrolled focal seizures: Prospective analysis of a randomized, double‐blind, placebo‐controlled study in a multinational Asian population

open access: yesEpilepsia, Volume 67, Issue 3, Page 1235-1245, March 2026.
Graphical representation of article highlights, including early response rates with adjunctive cenobamate. Abstract Objective To examine early responses to cenobamate therapy using prospective data from a dose–response study in Asian patients with focal seizures (YKP3089C035, C035) that employed a titration regimen starting at 12.5 mg/day.
Kensuke Kawai   +19 more
wiley   +1 more source

Home - About - Disclaimer - Privacy